Observations placeholder
Iressa
Identifier
019211
Type of Spiritual Experience
Background
A description of the experience
Gefitinib (ZD1839) trade name Iressa,, is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
As gefitinib is a selective chemotherapeutic agent, its tolerability profile is better than previous cytotoxic agents. Adverse drug reactions (ADRs) are acceptable for a potentially fatal disease [sic].
Acne-like rash is reported very commonly. Other common adverse effects (≥1% of patients) include: diarrhoea, nausea, vomiting, anorexia, stomatitis, dehydration, skin reactions, paronychia, asymptomatic elevations of liver enzymes, asthenia, conjunctivitis, blepharitis
Infrequent adverse effects (0.1–1% of patients) include: interstitial lung disease, corneal erosion, aberrant eyelash and hair growth.
On Jan, 2, 2016: 6,550 people reported to have side effects when taking Iressa. Among them, 14 people (0.21%) have Hallucination.
Time on Iressa when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 40.00% | 60.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Dec, 30, 2015: 6,550 people reported to have side effects when taking Iressa. Among them, 163 people (2.49%) have Death.
Time on Iressa when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 25.64% | 43.59% | 5.13% | 12.82% | 5.13% | 7.69% | 0.00% |